Bharat Biotech International
Our mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. We seek to lead innovation in biotechnology in order to lead the fight against disease with a focus on emerging markets. Typbar TCV is the worlds first clinically proven conjugate Typhoid vaccine and received WHO-Prequalification in January 2018. . ROTAVAC was Indias first and largest efficacy clinical trial on vaccines and Rotavac received WHO-Prequalification in January 2018.
| Active/Inactive | Active |
|---|---|
| CIN | U24230TG1996PLC023232 |
| exports02@bharatbiotech.com | |
| Office Location | Hyderabad, Telangana, India |
| Incorporation Year | 1996(28 yrs old) |
| Industry | Biotechnology |
| Company Employees | 1001-5000 |
| Website | http://bharatbiotech.com |
| Avg Revenue | $ 100M - 500M |
| Phone Number | 91 40 2778 4084 |
| Social Profile |
|
Introducing the industry's esteemed leaders, renowned for their extensive experience and insightful direction, driving the company towards a path of excellence.
D.K Roy is the Chief Executive Officer at Bharat Biotech.
Ajayreddy Parakala is the Chief Executive Officer at Bharat Biotech
Health Care & Insurance
Free Transport
Professional Training & Learning
Bharat Biotech International